Furthermore, the use of combination therapies, such as the dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 with abiraterone, enhances treatment efficacy by reducing intratumoral testosterone levels, inducing apoptosis, and inhibiting tumor growth in CRPC xenografts and patient-derived xenograft organoid models [32]. The gene discussed is DHODH; the disease is neoplasm.